LABP-104 250mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05019950 (ClinicalTrials.gov)	October 28, 2021	16/8/2021	Safety Tolerability and Pharmacokinetics of Oral LABP-104 in Healthy Adult Male and Female Volunteers	A Randomized, Placebo-Controlled, Double-Blind, Single-Center Study to Evaluate Safety Tolerability and Pharmacokinetics of Oral LABP-104 in Healthy Adult Male and Female Volunteers	Systemic Lupus Erythematosus	Drug: LABP-104 250mg;Drug: Placebo	Landos Biopharma Inc.	NULL	Completed	18 Years	64 Years	All	56	Phase 1	Australia